Stock Events

Stock Events

Xeris Biopharma

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6AugExpected

Q1 2026

Next

-0

0

0.01

0.01

Expected EPS

0.0106141963

Actual EPS

N/A

Financials

-0.07%Profit Margin

Unprofitable

2021

2022

2023

2024

2025

252.76MRevenue

-184,547.68Net Income

Analyst Ratings

7.59Average Price Target

The highest estimate is 7.59.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 69BN.MU. It's not an investment recommendation.

Palantir Technologies

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, competing directly with Xeris's inhaled and injectable therapies.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, providing products that compete in the diabetes therapeutic area with Xeris.

Sanofi is a global life sciences company that offers a range of diabetes solutions, including insulin therapies that compete with Xeris's glucagon rescue pen.

Eli Lilly and Company is a global healthcare leader that manufactures medicines for diabetes care, directly competing with Xeris's diabetes management products.

AstraZeneca operates in the biopharmaceutical sector, focusing on the development of new medicines for chronic diseases, including diabetes, thus competing with Xeris.

Merck & Co., Inc. offers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, including treatments for diabetes, making it a competitor.

Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose portfolio of medicines includes treatments for diabetes and cardiovascular diseases, areas where Xeris also operates.

Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products in various therapeutic areas, including those competing with Xeris's offerings.

Tandem Diabetes Care

Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, directly competing with Xeris's diabetes management solutions.

Insulet Corporation is an innovative medical device company focused on making the lives of people with diabetes easier through its Omnipod Insulin Management System, competing in the diabetes care market with Xeris.

About

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Show more...

CEO

Mr. John P. Shannon

Employees

435

Country

United States

ISIN

US98422E1038

Listings

0 Comments

Share your thoughts

FAQ

What is Xeris Biopharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Xeris Biopharma stocks are traded under the ticker 69BN.MU.

When is the next Xeris Biopharma earnings date?▼

Xeris Biopharma is going to release the next earnings report on August 06, 2026.

What were Xeris Biopharma earnings last quarter?▼

69BN.MU earnings for the last quarter are 0.01 EUR per share, whereas the estimation was -0 EUR resulting in a +464.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Xeris Biopharma revenue for the last year?▼

Xeris Biopharma revenue for the last year amounts to 252.76M EUR.

What is Xeris Biopharma net income for the last year?▼

69BN.MU net income for the last year is -184,547.68 EUR.

How many employees does Xeris Biopharma have?▼

As of July 18, 2026, the company has 435 employees.

In which sector is Xeris Biopharma located?▼

Xeris Biopharma operates in the Other sector.

When did Xeris Biopharma complete a stock split?▼

Xeris Biopharma has not had any recent stock splits.

Where is Xeris Biopharma headquartered?▼

Xeris Biopharma is headquartered in Chicago, United States.